Orthometrix's shock wave therapy:
This article was originally published in Clinica
The US FDA has given Orthometrix approval to market its high-energy shock wave system for relieving chronic plantar fasciitis (foot pain). The Orbasone device, a small and compact product, creates shock waves by using a spark plug enclosed in a soft membrane-covered dome filled with water; the dome is placed against the heel. The physician-supervised treatment typically takes about 30-40 minutes. The American Podiatric Medical Association in 2000 said that 38.6 million people in the US suffered from plantar fasciitis, noted the White Plains, New York-based firm. The Orbasone system is already cleared for sale in Europe, Asia and Canada.
You may also be interested in...
The first trial of the new Flash ultra-high dose radiation therapy with Varian Medical Systems’ ProBeam particle accelerator has begun. Agum Sharda, Varian’s senior director of Flash, says the technology could be a major advance for cancer patients.
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.